Imaged-based high-throughput screening for anti-angiogenic drug discovery

Current Pharmaceutical Design

Volumn 16, Issue 35, 2010, Pages 3958-3963

  Evensen, Lasse ^a   Link, Wolfgang ^b   Lorens, James B ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Angiogenesis; High content imaging; High throughput screening

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; COMBRETASTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPOTHILONE DERIVATIVE; FIBROBLAST GROWTH FACTOR; INDIRUBIN 3' MONOXIME; MATRIGEL; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SU 4312; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB; VINBLASTINE;

ANGIOGENESIS; AUTOMATION; CELL CULTURE; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG SCREENING; ENDOTHELIUM CELL; HIGH THROUGHPUT SCREENING; HUMAN; IMAGE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; TISSUE ENGINEERING; ZEBRA FISH;

ANGIOGENESIS INHIBITORS; ANIMALS; COCULTURE TECHNIQUES; DRUG DISCOVERY; HUMANS; MUSCLE, SMOOTH, VASCULAR;

EID: 79551628104     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794455030     Document Type: Review

References (37)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660.
2. Carmeliet P, Lampugnani MG, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999; 98: 147-57.
3. Lauren J, Gunji Y, Alitalo K. Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? Am J Pathol 1998; 153: 1333-9.
4. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
5. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6: 734-45.
6. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-44.
7. Dumas J, Dixon JA. VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures. Expert Opin Ther Pat 2005; 15: 647-58.
8. Motzer RJ. Sunitinib and axitinib in renal cell carcinoma. in renal cell carcinoma - molecular targets and clinical applications. In: Bukowski RM, Motzer RJ, Eds. Totowa, NJ: Humana Press 2009.
9. Wright JR, Jr. Almost famous: E. Clark Noble, the common thread in the discovery of insulin and vinblastine. CMAJ 2002; 167: 1391-6.
10. Fuchs DA, Johnson RK. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978; 62: 1219-22.
11. Reichenbach H, Hofle G. Discovery and development of the epothilones: a novel class of antineoplastic drugs. Drugs R D 2008; 9: 1-10.
12. Cirla A, Mann J. Combretastatins: from natural products to drug discovery. Nat Prod Rep 2003; 20: 558-64.
13. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev 2007; 6: 273-86.
14. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
15. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo- 1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3- carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46: 1116-9.
16. Sanz L, Pascual M, Muñoz A, et al. Development of a computerassisted high-throughput screening platform for anti-angiogenic testing. Microvasc Res 2002; 63: 335-9.
17. Evensen L, Micklem DR, Blois A, et al. Mural cell associated VEGF is required for organotypic vessel formation. PloS One 2009; 4: e5798.
18. Hegen A, Blois A, Tiron CE, et al. Efficient in vivo vascularization of tissue engineering scaffolds. J Tissue Eng Regen Med 2010; [Epub ahead of print].
19. Dong Z, Neiva KG, Jin T, et al. Quantification of human angiogenesis in immunodeficient mice using a photon countingbased method. Biotechniques 2007; 43: 73-7.
20. Gjerdrum C, Tiron C, Høiby T, et al. Axl is an essential epithelialto- mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 2010; 107: 1124-9.
21. Serbedzija GN, Flynn E, Willett CE. Zebrafish angiogenesis: a new model for drug screening. Angiogenesis 1999; 3: 353-9.
22. Ny A, Autiero M, Carmeliet P. Zebrafish and Xenopus tadpoles: small animal models to study angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312: 684-93.
23. Bayliss PE, Bellavance KL, Whitehead GG, et al. Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish. Nat Chem Biol 2006; 2: 265-73.
24. Tran TC, Sneed B, Haider J, et al. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res 2007; 67: 11386-92.
25. Janzen W. High Throughput screening, methods and protocols. 2002; 190.
26. Mishra KP, Ganju L, Sairam M, Banerjee PK, Sawhney RC. A review of high throughput technology for the screening of natural products. Biomedicine Pharmacother 2008; 62: 94-8.
27. Zanella F, Lorens JB, Link W. High content screening - seeing is believing. Trends Biotechnol 2010; 28(5): 237-45.
28. Orlidge A, D'Amore PA. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 1987; 105: 1455-62.
29. Korff T, Kimmina S, Martiny-Baron G, Augustin HG. Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J 2001; 15: 447-57.
30. Donovan D, Brown NJ, Bishop ET, Lewis CE. Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 2001; 4: 113-21.
31. Elbjeirami WM, West JL. Angiogenesis-like activity of endothelial cells co-cultured with VEGF-producing smooth muscle cells. Tissue Eng 2006; 12: 381-90.
32. Darland DC, Massingham LJ, Smith SR, et al. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Develop Biol 2003; 264: 275-88.
33. Evensen L, Micklem DR, Link W, Lorens JB. A novel imagingbased high-throughput screening approach to anti-angiogenic drug discovery. Cytometry A 77: 41-51.
34. Rabal O, Link W, Serelde BG, et al. An integrated one step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries. Mol BioSyst 2010; 6(4): 711-20.
35. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Develop Biol 2002; 248: 307-18.
36. Vogt A, Cholewinski A, Shen X, et al. Automated image-based phenotypic analysis in zebrafish embryos. Dev Dyn 2009; 238: 656-663.
37. Kalen, M., Wallgard E, Asker N, et al. Combination of reverse and chemical genetic screens reveals angiogenesis inhibitors and targets. Chem Biol 2009; 16: 432-41.